Edwards Lifesciences (NYSE:EW) Releases FY 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 2.950-3.050 for the period, compared to the consensus estimate of 2.970. The company issued revenue guidance of $6.5 billion-$6.9 billion, compared to the consensus revenue estimate of $6.7 billion. Edwards Lifesciences also updated its Q2 2026 guidance to 0.700-0.760 EPS.

Edwards Lifesciences Stock Down 2.3%

Shares of EW traded down $1.84 during mid-day trading on Thursday, hitting $79.69. 6,181,177 shares of the company’s stock were exchanged, compared to its average volume of 4,688,717. The firm has a fifty day moving average of $81.47 and a two-hundred day moving average of $82.17. Edwards Lifesciences has a twelve month low of $72.30 and a twelve month high of $87.89. The stock has a market cap of $45.95 billion, a price-to-earnings ratio of 43.55, a P/E/G ratio of 2.08 and a beta of 0.95. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts forecast that Edwards Lifesciences will post 2.96 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on EW. Truist Financial set a $89.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, February 11th. Wells Fargo & Company raised their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. UBS Group reiterated a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Robert W. Baird set a $90.00 target price on shares of Edwards Lifesciences in a research note on Monday, January 12th. Finally, Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $95.74.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $80.98, for a total transaction of $82,518.62. Following the completion of the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,747,975.32. This trade represents a 2.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the transaction, the vice president directly owned 21,266 shares of the company’s stock, valued at $1,782,941.44. The trade was a 53.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 86,058 shares of company stock valued at $7,118,636. Company insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently added to or reduced their stakes in EW. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after purchasing an additional 4,108,270 shares during the last quarter. Viking Global Investors LP bought a new position in Edwards Lifesciences during the 3rd quarter valued at about $238,688,000. Marshall Wace LLP increased its position in Edwards Lifesciences by 66.1% in the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock valued at $505,160,000 after acquiring an additional 2,359,128 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Edwards Lifesciences by 147.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,126,755 shares of the medical research company’s stock valued at $181,307,000 after acquiring an additional 1,267,918 shares in the last quarter. Finally, Artisan Partners Limited Partnership acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $99,462,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.